BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Oruka Therapeutics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Oruka Therapeutics's drugs run\, 
 from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07474792-1909@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:ORKA-002: Phase 2 readout est. (NCT07474792)
DESCRIPTION:ORKA-002\, phase 2\, Psoriasis.\nStudy: Dose Ranging Study of O
 RKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis\nEstimated pr
 imary completion: October 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/orka-002#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07474792
URL:https://assetmemo.bio/drug/orka-002#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07783542-1909@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:ORKA-002: Phase 2 readout est. (NCT07783542)
DESCRIPTION:ORKA-002\, phase 2\, Hidradenitis Suppurativa.\nStudy: ORKA-002
  Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppu
 rativa\nEstimated primary completion: October 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/orka-002#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07783542
URL:https://assetmemo.bio/drug/orka-002#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07933783-1909@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:ORKA-002: Phase 2 readout est. (NCT07933783)
DESCRIPTION:ORKA-002\, phase 2\, Psoriasis.\nStudy: An Open-label Study Wit
 h Maintenance Dosing of ORKA-002 in Participants With Moderate-to-Severe P
 laque Psoriasis\nEstimated primary completion: 1 July 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/orka-002#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07933783
URL:https://assetmemo.bio/drug/orka-002#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07449702-1812@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Avrukibart: Phase 2 readout est. (NCT07449702)
DESCRIPTION:Avrukibart\, phase 2\, Psoriasis.\nStudy: An Open-Label Extensi
 on Study of ORKA-001 in Participants With Plaque Psoriasis\nEstimated prim
 ary completion: May 2030. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/avrukibart#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07449702
URL:https://assetmemo.bio/drug/avrukibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
